stockrow
Friday 6 November 2026
Export HAE’s income statement to Excel — free account
Haemonetics Corporation
HAE Healthcare Medical Devices
Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025.
- Revenue
- +9.30%
- EPS
- +25.9%
- Free cash flow
- +20.4%
- Total debt
- +21.0%
Quarter to September 2026, against a year earlier
120.06
4.05
−3.26%
Follow HAE
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
46.59 | 36.59 | 27.76 | 21.96 |
+8 more quarters Free account |
P/S ratio |
3.47 | 2.52 | 1.99 | 2.84 | |
P/FCF ratio |
15.49 | 11.63 | 10.16 | 12.04 | |
P/Operating CF |
37.40 | 65.02 | 37.48 | 40.08 | |
P/B ratio |
5.33 | 4.06 | 3.34 | 4.11 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
4.08 | 3.22 | 2.72 | 3.27 | |
EV/EBITDA |
20.62 | 15.88 | 13.25 | 11.57 | |
EV/Operating CF |
16.36 | 13.25 | 12.39 | 12.71 | |
EV/FCF |
18.25 | 14.86 | 13.88 | 13.83 | |
Quick Ratio |
1.61 | 1.67 | 1.64 | 1.04 | |
Current Ratio |
2.84 | 3.08 | 2.95 | 1.75 | |
Net Debt/EBITDA |
0.00 | 11.18 | 226.86 | 5.79 | |
Debt/Assets |
46.22% | 49.43% | 50.90% | 36.93% | |
Debt/Equity |
1.24 | 1.40 | 1.53 | 1.01 | |
Asset Turnover |
0.57 | 0.56 | 0.55 | 0.53 | |
Operating CF/Net income |
2.77 | 1.59 | (3.52) | 2.09 | |
Capex/Depreciation |
— | (0.28) | (0.63) | (0.21) | |
Interest Coverage |
6.13 | 5.81 | (4.28) | 9.08 | |
Research and Development Expense of Revenue |
4.76% | 4.77% | 4.17% | 4.19% | |
Selling, General and Administrative Expense of Revenue |
33.08% | 35.05% | 34.92% | 32.20% | |
Intangible Assets out of Total Assets |
0.45 | 0.46 | 0.46 | 0.41 | |
Share Based Compensation of Revenue |
2.86% | 2.74% | 2.64% | 2.30% | |
Graham Net Nets |
(0.14) | (0.21) | (0.29) | (0.17) | |
Graham Number |
31.69 | 29.18 | 27.77 | 40.00 | |
Earnings Yield |
2.15% | 2.73% | 3.60% | 4.55% | |
Free Cash Flow Yield |
6.46% | 8.60% | 9.85% | 8.30% | |
Revenue per Share |
7.86 | 7.48 | 7.34 | 7.24 | |
Operating CF per Share |
2.82 | 1.15 | 1.50 | 2.00 | |
Capex per Share |
0.00 | (0.17) | (0.36) | (0.13) | |
Free Cash Flow per Share |
2.82 | 0.98 | 1.14 | 1.87 | |
Cash per Share |
5.73 | 4.92 | 5.20 | 7.77 | |
Shareholders Equity per Share |
19.75 | 18.45 | 16.88 | 19.48 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
19.75 | 18.45 | 16.88 | 19.48 | |
Free Cash Flow |
128.10 | 44.65 | 53.81 | 87.65 | |
Working Capital |
554.69 | 547.60 | 552.28 | 403.81 | |
Capital Expenditures |
— | (7.67) | (17.13) | (5.92) | |
Net Current Asset Value |
(656.58) | (717.47) | (764.73) | (635.76) | |
EV/EBIT |
31.90 | 27.12 | 23.18 | 17.15 | |
Capex to Sales |
0.00 | 0.02 | 0.05 | 0.02 | |
Price to Operating Income |
27.08 | 21.22 | 16.97 | 14.94 | |
| Other line items | |||||
Average Receivables |
216.01 | 208.41 | 209.76 | 203.83 | |
Average Payables |
66.67 | 51.17 | 59.03 | 55.84 | |
Average Inventory |
320.61 | 333.63 | 335.76 | 340.40 | |
Average Assets |
2,426.38 | 2,413.75 | 2,423.44 | 2,511.08 | |
Average Common Equity |
873.84 | 859.70 | 808.58 | 909.16 |
Columns are period end dates · fundamentals updated 5 Nov 2026